Assess an author's data and outputs

Concise author snapshot — Hannah Jebens

OpenAlex shows a small, recent publication record (5 works; 14 citations total; h-index ~1) concentrated on high-throughput FTIR methods for macro- and microplastics; the main peer‑reviewed article is in Analytical and Bioanalytical Chemistry (2024) and is open access.

Key evidence:

• 2024 FTIR high-throughput paper
• 2023 FTIR preprint

Author Review: Hannah Jebens — Evidence-based scientific critique

Primary evidence (selected)

• 2024 peer-reviewed FTIR methods paper
• 2023 FTIR preprint
• Zenodo data/code deposit (2023)

Detailed critique (strengths, weaknesses, blindspots)

1. Strength — Open science and reproducibility: co-authorship of open preprints and Zenodo data/code deposits demonstrates good reproducibility practices (data + code are available for independent verification) which raises the trustworthiness of the methods-focused work (2023 FTIR preprint; Zenodo data/code deposit (2023)).
2. Strength — Method focus with immediate practical utility: the 2024 article addresses throughput gaps in FTIR identification for larger microplastics and macroplastics — an operationally useful advance if widely reproducible (2024 peer-reviewed FTIR methods paper).
3. Weakness — small independent citation footprint and limited author-level metrics: OpenAlex reports 5 works and 14 citations overall with h-index ~1 for the top OpenAlex profile, indicating early-stage citation impact; this limits claims about broad influence or leadership in the field (metadata summary from OpenAlex; underlying DOIs above show the main contributions).
4. Weakness — author position and contribution ambiguity: Jebens appears as a middle author on the principal outputs; middle-author contributions can be substantial but the metadata alone cannot specify exact contributions (no ORCID listed). This makes author-level attribution of conceptual leadership uncertain.
5. Blindspot — cross-lab validation and generalizability: the methods paper is promising, but broad adoption requires independent replication across labs, different instrument models, and environmental sample types; current evidence shows a single coordinated group and dataset deposits but not yet multi-lab intercomparisons.
6. Potential biases to watch: method development papers can emphasize operational advantages; assessors should check for selective performance reporting, unreported failure modes, and whether the provided datasets include diverse, real-world samples (the article lists reference_count=35 and supplemental data; raw data deposits mitigate but do not eliminate these risks).

What the metrics say (interpretation)

OpenAlex profile shows: works_count = 5; cited_by_count = 14; h_index ≈ 1 for the top author record — consistent with a researcher who is early in an active, methodologically-focused publishing trajectory rather than an established, highly-cited senior leader. The presence of OA code/data and a 2024 peer-reviewed paper indicates strong alignment with transparency and reproducible-methods norms.

Practical recommendations for evaluating Jebens' future work

• Look for multi-lab validation or independent uptake citations as evidence of generalizability.
• Examine contribution statements (author contributions / CRedit) in future papers to judge role and leadership.
• Re-run or inspect the Zenodo code/data to confirm reproducibility for your samples/instruments.

Direct source links

• 2024 Analytical & Bioanalytical Chemistry paper (OA PDF)
• 2023 ChemRxiv preprint
• Zenodo data/code (2023)